Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone206-286-2501
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
Next Earnings DateN/A
OptionableNot Optionable
Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions
What is Poniard Pharmaceuticals' stock symbol?
Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."
Has Poniard Pharmaceuticals been receiving favorable news coverage?
News headlines about PARD stock have been trending very negative this week, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Poniard Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Poniard Pharmaceuticals.
Who are some of Poniard Pharmaceuticals' key competitors?
Some companies that are related to Poniard Pharmaceuticals include Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Mereo BioPharma Group (MREO), Myrexis (MYRX), NeuroVive Pharmaceutical (NEVPF), Pivotal Therapeutics (PVTTF) and Processa Pharmaceuticals (PCSA).
Who are Poniard Pharmaceuticals' key executives?
Poniard Pharmaceuticals' management team includes the folowing people:
- Dr. Paul G. Abrams, Exec. Officer
How do I buy shares of Poniard Pharmaceuticals?
Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Poniard Pharmaceuticals' stock price today?
One share of PARD stock can currently be purchased for approximately $0.09.
What is Poniard Pharmaceuticals' official website?
How can I contact Poniard Pharmaceuticals?
Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]
MarketBeat Community Rating for Poniard Pharmaceuticals (OTCMKTS PARD)
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.
